Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)

Author:

Sharma Ashish1ORCID,Holz Frank G2,Regillo Carl D3,Freund K Bailey45,Sarraf David67,Khanani Arshad M.8ORCID,Baumal Caroline9,Holekamp Nancy10ORCID,Tadayoni Ramin11,Kumar Nilesh12ORCID,Parachuri Nikulaa13,Kuppermann Baruch D14,Bandello Francesco,Querques Giuseppe,Loewenstein Anat,Özdek Şengül,Rezai Kourous,Laurent Kodjikian,Bilgic Alper,Lanzetta Paolo,Zur Dinah,Yannuzzi Nicolas,Corradetti Giulia,Kaiser Peter,Hilely Assaf,Boyer David,Rachitskaya Aleksandra,Chakravarthy Usha,Wintergerst Maximilian,Sarao Valentina,Parolini Barbara,Mruthyunjaya Prithvi,Nguyen Quan Dong,DO Diana,Keane Pearse A,Hassan Tarek,Sridhar Jayanth,Eichenbaum David,Grewal Dilraj,Splitzer Martin, ,

Affiliation:

1. Lotus Eye Hospital and Institute, Coimbatore, India

2. Department of Ophthalmology, University of Bonn, Bonn, Germany

3. The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA

4. Vitreous Retina Macula Consultants of New York, New York, USA

5. Department of Ophthalmology, NYU Grossman School of Medicine, New York, NY, USA

6. Stein Eye Institute, UCLA, Los Angeles, CA, USA

7. Department of Ophthalmology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

8. Sierra Eye Associates, Reno, NV, USA and The University of Nevada, Reno School of Medicine, Reno, NV, USA

9. Tufts University School of Medicine, New England Eye Center, Boston, Massachusetts

10. Pepose Vision Institute, St. Louis, Missouri, USA

11. Université Paris Cité, AP-HP, Lariboisière, St Louis and Fondation Adolphe de Rothschild hospitals, Paris, France

12. Madhavi Netralaya, Ara, India

13. Department of Vitreoretina, Sankara Eye Hospital, Coimbatore, India

14. Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Reference29 articles.

1. Biosimilars for Retinal Diseases: An Update

2. FDA approves Samsung bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) https://investors.biogen.com/news-releases/news-release-details/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11. September 07, 2022

3. Ranibizumab Biosimilar (Byooviz) gains EU marketing authorization. https://www.centerforbiosimilars.com/view/samsung-bioepis-byooviz-gains-ema-marketing-authorization. cited 2022 Sept 07

4. FDA approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the first and only interchangeable biosimilar to Lucentis® for all five indications, with 12 months of interchangeability exclusivity. https://investors.coherus.com/news-releases/news-release-details/fda-approves-coherus-cimerlitm-ranibizumab-eqrn-first-and-only. Cited 2022 Sept 07

5. European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis. https://www.formycon.com/en/press-release/european-commission-approves-fyb201-ranivisio1-ranivisio-ranibizumab-a-biosimilar-to-lucentis2/. Cited 2022 Sep 07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3